Comparing Sinovac Biotech (NASDAQ:SVA) and Its Competitors

Sinovac Biotech (NASDAQ: SVA) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Sinovac Biotech to related companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, risk, profitability and earnings.

Profitability

This table compares Sinovac Biotech and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Sinovac Biotech Competitors -13,405.03% 38.07% -20.60%

Analyst Recommendations

This is a summary of current recommendations for Sinovac Biotech and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech 0 0 0 0 N/A
Sinovac Biotech Competitors 121 766 1637 59 2.63

As a group, “Biopharmaceuticals” companies have a potential upside of 12.00%. Given Sinovac Biotech’s peers higher possible upside, analysts clearly believe Sinovac Biotech has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Sinovac Biotech and its peers gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sinovac Biotech $64.02 million -$837,000.00 -87.74
Sinovac Biotech Competitors $579.41 million $241.76 million -7.09

Sinovac Biotech’s peers have higher revenue and earnings than Sinovac Biotech. Sinovac Biotech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

30.7% of Sinovac Biotech shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sinovac Biotech peers beat Sinovac Biotech on 6 of the 8 factors compared.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply